AnaptysBio, Inc.
ANAB
$44.25
$0.491.12%
NASDAQ
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
12/4/2025
-
MarketBeat
12/4/2025
-
MarketBeat
12/2/2025
-
Tickeron - Stocks
12/2/2025
-
Simply Wall St
A Look at AnaptysBio's Valuation as Litigation With GSK Over Jemperli Royalties Draws Investor Focus
11/28/2025
-
Simply Wall St
11/27/2025
-
MarketBeat
11/26/2025
-
TipRanks Financial Blog
11/25/2025
-
Globe Newswire
11/25/2025
-
MarketBeat
11/25/2025
-
MarketBeat
11/25/2025
-
MarketBeat
11/25/2025
-
Tickeron - Stocks
11/25/2025
-
Tickeron - Stocks
11/25/2025
-
Tickeron - Stocks
11/25/2025
-
MarketBeat
11/24/2025
-
GuruFocus
11/23/2025
-
MarketBeat
11/22/2025
-
MarketBeat
11/22/2025
-
Tickeron - Stocks
11/22/2025
-
Tickeron - Stocks
11/21/2025
-
GuruFocus
11/21/2025
-
TipRanks Financial Blog
11/21/2025
-
TipRanks Financial Blog
11/21/2025
-
The Fly
11/21/2025
-
GuruFocus
Income Statement
Total Revenue (TTM)
EBITDA (TTM)
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Tuesday, November 4, 2025
Period Date
Tuesday, September 30, 2025
Next Filing
Week of Feb 23 and 27 (est)
Price History
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
5-Year Total Return
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
858 362 6295
Address
10770 Wateridge Circle
San Diego, CA 92121-5801
San Diego, CA 92121-5801
Country
Year Founded
Business Description
Sector
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in...
more